Stocks · News reference
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Roivant announced positive Phase 2 trial results for mosliciguat, demonstrating improved walk distance and reduced cardiac strain in PH-ILD.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $46
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $47
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.